title: [Is adaptive intensity-modulated radiotherapy for uterine cervix carcinoma necessary?].
abstract: OBJECTIVE
  To observe on ten patients, the changes of different pelvic structures during a Stade IB2-IIB cervix cancer tomotherapy course delivering 60Gy over 5.5 weeks and evaluate the rationale of adaptive treatments.
  
  
  METHODS
  Each of the six weekly mega voltage CT-scan (MVCT) exams performed the same day of the week were analyzed. The centro-pelvic CTV volume was contoured as well as the organs at risk (OAR). The dose delivered was recalculated while those to 2%, 50% and 98% of the centro-pelvic CTV as well as to 2 cm(3), 10 cm(3) and 50 cm(3) of the OAR were analyzed.
  
  
  RESULTS
  The mean decrease in volume of the centro-pelvic CTV was 13% and non-significant (P>0.2). However four tumors decreased from 21% to 42%. This decrease was centripetal. Likewise, the fraction doses to 2%, 50% and 98% were respectively 2.14±0.08Gy, 2.02±0.14 Gy, 1.8±0.34Gy at week 1 and 2.13±0.1 Gy, 2.06±0.12Gy, 1.88±0.24Gy at week 6 (P>0.2). The doses delivered to 2 cm(3), 10 cm(3) and 50 cm(3) of the different OAR did not change at a significant level (P>0.05) too, except the dose to 50 cm(3) of non-sigmoid bowel moving from 1.69±0.16Gy at week 1 to 1.78±0.14Gy at week 6 (P=0.05).
  
  
  CONCLUSIONS
  As a whole, adaptive therapy does not seem mandatory in this population of stages IB2-IIB cancers. A complementary study on more advanced stages is however necessary.
authors.affiliation: Service universitaire de radiothérapie et curiethérapie, centre Oscar-Lambret, 3, rue Frédéric-Combemale, 59000 Lille, France.
authors.forename: F
authors.initials: F
authors.lastname: Le Tinier
authors.forename: N
authors.initials: N
authors.lastname: Reynaert
authors.forename: B
authors.initials: B
authors.lastname: Castelain
authors.forename: E
authors.initials: E
authors.lastname: Lartigau
authors.forename: T
authors.initials: T
authors.lastname: Lacornerie
authors.forename: P
authors.initials: P
authors.lastname: Nickers
mesh_terms: D002294:Carcinoma, Squamous Cell / Q000473:pathology / Q000532:radiotherapy*; D005260:Female; D006801:Humans; D007422:Intestines / Q000528:radiation effects; D058958:Organs at Risk; D011879:Radiotherapy Dosage; D011880:Radiotherapy Planning, Computer-Assisted; D050397:Radiotherapy, Intensity-Modulated / Q000379:methods*; D002583:Uterine Cervical Neoplasms / Q000473:pathology / Q000532:radiotherapy*